C4 Therapeutics, Inc. (CCCC) Stock

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical firm headquartered in Watertown, Massachusetts, specializes in pioneering novel therapeutic candidates designed to degrade disease-causing proteins across a spectrum of conditions including cancer and neurodegenerative diseases. The company's flagship product candidate, CFT7455, is an orally bioavailable MonoDAC degrader targeting IKZF1 and IKZF3 proteins. Currently in Phase 1/2 trials, CFT7455 aims to address multiple myeloma and various types of non-Hodgkin lymphomas such as peripheral T-cell lymphoma and mantle cell lymphoma.

In addition to CFT7455, C4 Therapeutics is advancing a robust pipeline of candidates including CFT8634, an orally bioavailable BiDAC degrader targeting BRD9 for synovial sarcoma and SMARCB1-deleted solid tumors. The company is also developing CFT1946, a BiDAC degrader targeting V600X mutant BRAF for melanoma, NSCLC, colorectal cancer, and other solid tumors, along with CFT8919, an allosteric, mutant-selective BiDAC degrader of EGFR with L858R mutation for NSCLC. Beyond these, C4 Therapeutics is engaged in earlier-stage programs focusing on RET degraders to combat various cancers.

Founded in 2015, C4 Therapeutics has established strategic collaborations with industry leaders such as F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Biogen MA, Inc., and Calico Life Sciences LLC. These partnerships underscore C4 Therapeutics' commitment to advancing cutting-edge therapies that target protein degradation mechanisms, offering new avenues for treating challenging diseases with high unmet medical needs.